These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. Kisor DF Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141 [TBL] [Abstract][Full Text] [Related]
23. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318 [TBL] [Abstract][Full Text] [Related]
24. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113 [TBL] [Abstract][Full Text] [Related]
25. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia. Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734 [No Abstract] [Full Text] [Related]
26. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158 [TBL] [Abstract][Full Text] [Related]
30. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Lech-Maranda E; Korycka A; Robak T Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505 [TBL] [Abstract][Full Text] [Related]
31. Nelarabine use in leukemias. Kisor DF Drugs Today (Barc); 2006 Jul; 42(7):455-65. PubMed ID: 16894400 [TBL] [Abstract][Full Text] [Related]
34. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462 [TBL] [Abstract][Full Text] [Related]
35. Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine. Hebert ME; Greenberg ML; Chaffee S; Gravatt L; Hershfield MS; Elion GB; Kurtzberg J Transplantation; 1991 Oct; 52(4):634-40. PubMed ID: 1926342 [TBL] [Abstract][Full Text] [Related]
36. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Reilly KM; Kisor DF Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909 [TBL] [Abstract][Full Text] [Related]
37. Clofarabine in pediatric acute leukemia: current findings and issues. Hijiya N; Barry E; Arceci RJ Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543 [TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663 [TBL] [Abstract][Full Text] [Related]
39. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms. Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941 [TBL] [Abstract][Full Text] [Related]
40. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]